Circulating Fetal Cells and Breast Cancer

Study Overview
=================
Brief Summary
-----------------
After pregnancy, fetal cells remain in a woman's body for years. These cells may be involved in different physiological situations (e.g. wound healing) and diseases (e.g. cancer).The study will evaluate the level of circulating fetal immune cells in patients with breast cancer vs controls with benign breast tumors, and further characterize these fetal cells. Patients participation will be limited to accepting that an additional blood sample is collected on the day of their preop consultation and blood test.

Detailed Description
-----------------
Breast cancer is the most common cancer in the female population. The protective mechanism associated with pregnancy is not fully understood. During pregnancy fetal cells cross the placental barrier and may remain in the maternal circulation even for up to 30 years after childbirth. This phenomenon is called fetal microchimerism. The presence of circulating fetal cells would have a protective role against breast cancer. However, their phenotype and role in the anti-tumor response is not explored. The objective of the study is to identify the sub-population (s) of circulating fetal immune cells that may have an impact on the processes of carcinogenesis in breast cancer, in the context of fetal microchimerism.

Official Title
-----------------
Fetal Microchimerism and Fetal Stem Cells in Breast Cancer: Analysis of Circulating Fetal Cell Sub-populations in Women With Breast Cancer. CIRCULATING FETAL CELLS AND BREAST CANCER

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women aged 18-50 having had a male child informed and not having objected to participating in the research. Patients: - having a diagnosis of breast cancer Controls: operated on for benign breast tumors cancer free Exclusion Criteria: autoimmune disease immunomodulatory treatment history of cancer other than breast cancer ongoing hormonal treatment women not affiliated to the social security under AME (state medical aid) under tutorship / curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>women 18-50 years with previous history of a male birth scheduled for malignant breast tumor surgery | Other: Blood sample<br>* As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.<br>|
| Controls<br>women 18-50 years with previous history of a male birth scheduled for benign breast tumor surgery or cancer free | Other: Blood sample<br>* As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentages of fetal cells in each immune cell subpopulation. | Using fluorescence activated cell sorting method. | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activation markers. | Using immunocytochemistry method. | 3 years | 
| Cytotoxicity markers. | Using immunocytochemistry method. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, Microchimerism, Hematopietic fetal cells